Please assess the completion status of the following clinical trial:

Trial Title: tPA by Endovascular Administration for the Treatment of Submassive PE Using CDT for the Reduction of Thrombus Burden

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Willing and able to provide informed consent;~2. Age 18 to ≤ 75 years of age;~3. PE symptom duration ≤ 14 days.~4. Filling defect in at least one main or lobar pulmonary artery as determined by contrast enhanced chest CT (CTA);~5. RV/LV diameter ratio ≥ 0.9 by CTA as determined by the investigative site;~6. Willing and able to comply with all study procedures and follow-up.~Exclusion Criteria:~1. CVA or TIA within one (1) year;~2. Head trauma, active intracranial, or intraspinal disease ≤ one (1) year prior to inclusion in the study;~3. Active bleeding from a major organ within one (1) month prior to inclusion in the study;~4. Intracranial condition(s) that may increase the risk of bleeding (e.g., neoplasms, arteriovenous malformations, or aneurysms);~5. Patients with bleeding diatheses;~6. Hematocrit \< 30%;~7. Platelets \< 100,000/μL;~8. INR \> 1.5 if currently on warfarin (Coumadin®);~9. aPTT \> 50 seconds in the absence of anticoagulants;~10. Major surgery ≤ 14 days prior to inclusion in the study;~11. Serum creatinine \> 2.0mg/dL;~12. Clinician deems high-risk for catastrophic bleeding;~13. History of heparin-induced thrombocytopenia (HIT Syndrome);~14. Pregnancy;~15. SBP \< 90 mmHg \> 15 minutes within two (2) hours prior to BEC procedure and is not resolved with IV fluids;~16. Any vasopressor support;~17. Cardiac arrest (including pulseless electrical activity and asystole) requiring active cardiopulmonary resuscitation (CPR) during this hospitalization at treating institution and/or referring institution;~18. Evidence of irreversible neurological compromise;~19. Life expectancy \< one (1) year;~20. Use of thrombolytics or glycoprotein IIb/IIIa inhibitor within 3 days prior to inclusion in the study;~21. Use of non-vitamin K oral anti-coagulants (NOACs), such as rivaroxaban (Xarelto®), apixaban (Eliquis®), dabigatran (Pradaxa®), edoxaban (Savaysa®) within 48 hours prior to inclusion in the study;~22. Profound bradycardia requiring a temporary pacemaker and/or inotropic support;~23. Previous enrollment in this study;~24. Morbidly obese patient who by the judgement of the investigator is high risk for bleeding;~25. BMI \> 45kg/m2;~26. Absolute contraindication to anticoagulation;~27. Uncontrolled hypertension defined as SBP \> 175mmHg and / or DBP \> 110mmHg with pharmacotherapy within two (2) hours prior to inclusion in the study;~28. Currently participating in another study;~29. Any arterial line placement;~30. Current positive COVID diagnosis, or ≤ 8 weeks negative of COVID, or \> 8 weeks from positive COVID test and with current symptoms, or current active viral pneumonia on chest CT scan;~31. In the opinion of the investigator, the subject is not a suitable candidate for the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- BEC Treatment (Type: EXPERIMENTAL): The Bashir™ Endovascular Catheter is a device intended for the localized infusion of therapeutic agents into the pulmonary artery.

Based on this trial design, predict the completion outcome and termination type (if applicable).